Durham.

PositionTriangle

DURHAM -- Chimerix raised $16.1 million to continue developing its lead product, an antiviral drug. Its pipeline also includes treatments for HIV and hepatitis C. Funding came from existing investors Canaan Partners, Alta...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT